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Abstract 
Background: The goal of ART therapy is sustained viral load suppression with good 
immunological and clinical response. This optimal response to therapy results in the 
prevention of emergent A R T  drug-resistant mutations, decrease morbidity, and AIDS-
related mortality and sustained retention on ART. Kenya, like most countries in Sub-
Saharan Africa, has scaled-up the use of ART and is currently implementing a “Test and 
Treat” strategy in which any client identified and confirmed with an HIV diagnosis is 
initiated ART. Few studies have been carried out to ascertain the response of HIV patients 
initiating treatment in resource-limited settings. Moreover, it has been demonstrated that a 
certain proportion of patients fail to adequately respond to therapy and therefore require 
therapy modification.  
Aim: To assess treatment outcomes and calculate retention of HIV infected adult patients’ 
(15 years and above) initiating ART at Kakamega County General Hospital. The primary 
study outcome was the treatment outcome of patients-initiated ART two to three years prior 
to the study; while, the role of WHO criteria for screening treatment failure was assessed as 
a secondary outcome. 
Methods: This was a retrospective cohort study in which patients initiating ART between 
June 2014 and March 2015 were followed up until they were censored or study closed in 
August 2017. 284 patients were enrolled in the study after accurately matching information 
in their clinic files and the electronic medical record. Data were collected from patient 
records using a chart abstraction tool and transferred to an Access database from where the 
cleaning and validation of entries were done. Data from Access was transferred to STATA 
15.1 for analysis. Descriptive statistics and inferential statistics were then performed to 
answer the research questions.  
Results: More female patients (57%) initiated ART. Nearly all patients started ART based 
on CD4 count, 93%. About 10% of those starting ART had severe (WHO stage 3 or 4) OI. 
TB was the commonest severe OI, followed by Kaposi Sarcoma, diarrhea and meningitis at 
7%, 2.5%, and 2.1% respectively. Overall, only 15% of patients starting ART had an OI. 
TDF based regimen was the preferred ART regimen initiated to 77% of the patients. The 
initiation of ART was associated with a 2-fold reduction in the incidence of OIs. The 
majority of patients had good CD4 count increases on initiating ART, 97.9% over the 
follow-up period. Patients with recurrent OIs were less likely to have suboptimal CD4 
counts. VL was detectable in 17% of patients. Up to 80% of clients failing ART were 
identified clinically. Retention in the ART clinic was 89% and this was similar across ages 
and gender. The death of patients accounted for 55% attrition at an incidence rate of 1.9 per 
1000 person-months of follow-up.   
Conclusion and Recommendation: Initiating patients on ART has phenomenal clinical, 
immunological and virological outcomes as it has already been demonstrated the world 
over. However, there is still a number of patients who continue to fail therapy, thus 
necessitating a change to a more expensive drug regimen. Hence, clinical surveillance for 
ART failure should be strengthened to promptly recognize patients who require additional 
clinical and psychosocial care for the betterment of their health and program outcomes.  
http://etd.uwc.ac.za/
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Operational Definition of Terms 
Clinical response consists of the observable, reportable and measurable parameters such as 
height, weight, body mass index, the occurrence of opportunistic infections; improvement, 
worsening, the emergence or the disappearance of diseases and/or conditions that are 
related with HIV; including adherence to therapy. Good response implies an improvement 
in the health of an HIV infected person, while poor response, a deterioration in progress. 
First line Antiretroviral Therapy is the first antiretroviral regime given to HIV naïve 
patients, i.e. patients who have never been g i v en  any form of the antiretroviral drug. 
This is also called Highly Active Antiretroviral Therapy (HAART) first line regime. 
Immunological response is used to describe the progression of HIV in the form of CD4 
count. A good immunologic response is qualified by the sustained increase in CD4 over a 
given period, usually at least 100 – 150 per year and more so in the initial years of therapy. 
Opportunistic infections are those diseases s u ch  a s  t u b e r cu l o s i s ,  p n eu m o n i a ,  
m en i n g i t i s ,  o r a l  t h r u s h  that attack HIV immune-compromised persons who have a 
low immunity more frequently and severely than in a non-HIV infected individual. 
Therapy – word therapy is used interchangeably with antiretroviral therapy. 
Treatment failure occurs when a patient who has been taking ART for at least 6 months fails 
to show the good clinical, immunologic or virological response expected. Such a patient may 
experience the stagnation of the body immune cells or a worsening. 
Virological response is a sustained viral load suppression in a patient who has been on ART 
for at least six months. The opposite would be a virological failure, in which such a patient’s 
viral load is no longer detectable. 
http://etd.uwc.ac.za/
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CHAPTER ONE 
A DESCRIPTION OF THE STUDY 
1.1. Introduction 
Human Immunodeficiency Virus (HIV) remains a virus of global health focus (1). There are 70 
million people who are infected with the virus, and about 35 million people have lost their 
lives since 1981 (2) because of it. As at December 2015, about 37 million people were living 
with HIV the world over. According to Global Health Observatory (GHO) data of 2018, nearly 
one in every 25 adults i n  Sub-Saharan Africa lives with HIV, which contributes to 70 percent 
of people living with the disease. An HIV infection is usually diagnosed through blood tests, but 
the infection has no cure.   
Effective treatment with antiretroviral drugs can control the virus so that people with HIV can 
enjoy healthy and productive lives (3). In 2011, more than eight million people living with 
HIV were receiving antiretroviral therapy (ART) in low and middle-income countries (4); this 
number was almost double (15 million) at the end of 2015 (1). Attaining and sustaining viral 
suppression is the goal of antiretroviral therapy (ART); which is the optimal response to 
therapy, that results in the avoidance of the emergence of drug resistance mutations (5).  
Treatment guidelines in resource- rich settings recommend VL monitoring every 3–6 
months (6). However, in settings like Sub-Saharan Africa and India, treatment efficacy has 
until recently been monitored through immunological markers like CD4+ T cell count, (7), 
and clinically. Nonetheless, short-term outcomes of ART in resource-constrained settings are 
comparable to those in resource-rich settings (8,9). Possible setbacks result from the lack of 
greater than 95% adherence to therapy, drug-drug interactions, drug-food interactions, 
http://etd.uwc.ac.za/
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immunological factors, possible undiagnosed opportunistic infections, and the nature of patient-
physician engagement (10–13). 
1.1.1. HIV Infection and ART Status in Kenya 
The HIV estimates report of  2014 (14) ranked Kenya among the high burden countries in Africa with 
a total of 1, 206, 968 adults and 159, 700 children living with HIV. As at the end of 2015, the burden 
had increased to 1.5 million Kenyans living with HIV (15). Among the People Living with HIV 
(PLWH) in Kenya, (14) the AIDS survey of 2012 established that around 89% were going to an HIV 
clinic; but, only 77% of the PLWH were aware of their HIV status. ART coverage among those who 
already knew their HIV status was about 85% (15). Yet, among clients on ART in Kenya, viral 
suppression (a function of retention and adherence to ART) was about 60% (16,17). In 2016, Kenya 
adopted universal ART coverage for PLWH (18). Use of first-line ART has now been 
scaled-up in Kenya. Nevertheless, there is a paucity of data on the course of disease 
progression among PLWH for such therapies (19). Yet some patients on ART require therapy 
modification due to failed therapy manifested as a sub-optimal virologic response, poor CD4 
count response and/or re-emergence of opportunistic infections (20). 
Kenya has the second largest ART country program after South Africa with about 900,000 
people on antiretroviral therapy (21). Large numbers of patients have been put on first-line 
antiretroviral therapy in the past five years in a bid to fast-track the provision and 
accessibility of these drugs (21,22). Consequently, many deaths and HIV related infections 
have been averted (23). In a study on ART resistance conducted in Coastal Kenya (24), less 
than 5.0% of clients were found to have drug-resistant HIV. However, another study carried 
out in Western Kenya established a drug resistance of 9.2% (25). Clearly, as more people are 
http://etd.uwc.ac.za/
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put on ART, there is also an increasing number of patients failing therapy (21).  
Unfortunately, ART drug resistance has been shown to compromise the effectiveness 
of standard antiretroviral regimens (24,26–28). 
1.2. Rationale for ART 
First-line ART is given to HIV infected clients for five main reasons (20): First, clinically, 
where ART has been shown to prolong life and improve the quality of life (29). Secondly, 
virologically to achieve the greatest reduction in viral load (preferably less than 50 c/ml) for 
as long as possible to halt disease progression or delay progression (30). Thirdly, 
immunologically ART reconstitutes the immunity that is both quantitative (increases CD4 cell 
count to normal range) and enhances the pathogen-specific immune response (22,31). Fourthly, 
therapeutically, to focus on a rational selection of drugs to meet clinical, virologic and immune 
goals while maintaining future treatment options, limiting drug toxicity and facilitating 
adherence (32); and epidemiologically to a t t a i n  a  reduction in HIV transmission (33).  
1.3. Problem Statement 
Although most patients are on first-line ART, it is expected that the demand for second-line 
regimens will increase over time. This is the case despite the gains made from potent first-line 
ART (34). Several studies have suggested that some patients on ART fail therapy (19,25). In a 
retrospective cohort study in Ethiopia, 4.1% of people living with HIV (PLWH) on ART had 
failed therapy (35); whereas, in a cross-sectional study conducted in Kenya 6.9% failed; 
which was similar to a European cohort that reported 10.0% failure (25,27). Among those 
failing first-line, about 46% of them went on to fail second-line ART due to increased side-
effects, drug resistance and treatment fatigue (36). Moreover, they had increased morbidity 
http://etd.uwc.ac.za/
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and mortality (35). Despite the capacity to promptly identify ART treatment failure through 
clinical and immunological criteria (29,37), “b e t t e r  evidence and more data are required 
before more specific recommendations can be made, particularly for resource-limited settings 
where routine viral load monitoring is not routinely available”. Early identification and 
prevention of treatment failure will help sustain the effectiveness of ART and preserve 
treatment options (35,38,39). 
1.4. Study Aim and Objectives 
The aim of this study was to assess treatment outcomes and calculate retention on first-line 
ART among adults (15 years and above) living with HIV initiated on first-line antiretroviral 
therapy at Kakamega County General Hospital (KCGH) between July 2014 and March 2015. 
By using and documenting basic criteria for monitoring response on ART treatment, obtained 
results provide an insight on HIV disease progression amongst patients on ART, and, the 
retention on therapy. Predictors for disease progression are highlighted and recommendations 
made on how resource-poor settings may improve the quality of care and follow up of ART 
patients. 
The specific objectives of the present study were: 
• To measure the virologic response to therapy among HIV infected patients initiated first-
line ART aged 15 years and above (adults)  between July 2014 and March 2015 at KCGH; 
• To determine the immunologic response to therapy among adults living with HIV 
initiated first-line ART between July 2014 and March 2015 at KCGH; 
• To assess clinical response to antiretroviral therapy among adults living with HIV 
initiated first-line ART between July 2014 and March 2015 at KCGH, and, 
http://etd.uwc.ac.za/
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• To calculate the retention of adults living with HIV initiated first-line ART between July 2014 and 
March 2015 at KCGH.  
1.5. Study Setting 
The study was conducted at Kakamega County General Hospital (KCGH). KCGH is situated in 
Western Kenya, Kakamega County, Lurambi Sub-County. It is the referral center of the 
county. KCGH has a catchment population of 170,515 according to their Annual Work Plan 2 
of 2014-15. The hospital provides both curative and preventive services since it became a 
fully-fledged hospital in 2007, (40,41) offering general outpatient and inpatient care, maternal 
and child health services, immunization, sexual and reproductive health, minor surgical care, 
basic laboratory services, and HIV and Tuberculosis (TB) services. On average, the hospital 
serves about 5000 patients per month. It has an in-patient bed capacity of 449. The HIV 
Comprehensive Care Centre (CCC) is sandwiched between the female and paediatric wards, 
and, the continuous medical education hall. At the time of the study, there were about 3000 
adolescents and adults on ART.  
Monitoring of treatment response at KCGH is done through three prescribed avenues. People 
living with HIV (PLWH) on ART are assessed clinically, through CD4 and VL monitoring. 
Despite challenges accessing VL testing, secondary networks have been set up and are used. 
Through sample networking for VL testing, at least all PLWH initiated ART have a chance to 
have their VL samples collected and tested within six months. That is why it was possible to 
assess the clinical, immunological and virological status and progression (treatment 
response) of the clients on ART in resource-limited settings like KCGH; thus, making it 
possible to compare findings to those in resource-rich settings (8,9).   
http://etd.uwc.ac.za/
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CHAPTER TWO 
LITERATURE REVIEW 
2.1 Introduction 
The future of Kenya towards the fight of HIV mainly rests on efforts towards preventing 
new infections among millions of young people who will become sexually active in the next 
few years (42).  Although fewer young people are becoming infected in Kenya than at 
earlier stages of the pandemic (34,43), the disease represents a continuing threat to young 
people in Kenya especially those 20 – 24-year-old people among whom more than1 person 
in 25 (4.2%) is already infected when they enter young adulthood (44). There is the need to 
continue providing antiretroviral therapy (ART) as prevention (treatment as prevention) (45–
47).  
2.2 Initiation of ART 
Initiation of ART in Kenya has evolved over time. According to the Kenya Brief on ART, 
adults were initiated ART if they had CD4 cell counts ≤ 200 cells / mm3 between years 2002 
and 2005; ≤ 200 cells / mm3 or a World Health Organization (WHO) clinical stage 4, or 
WHO stage 3 dependent on CD4 ≤ 350 cells / mm3 following national guidelines of 2005 
through 2007 (48–50). From November 2007 to October 2010, ART was initiated for any 
adult with a WHO stage 3 or 4 and/or CD4 ≤ 250 cells / mm3. the 250 cells / mm3 was revised 
upward to ≤ 350 cells / mm3 in October 2010 (7,51,52). From June 2014 to June 2016, ART 
was initiated to all clients with a CD4 ≤ 500 cells / mm3 or with WHO stage 3 or 4, or to 
pregnant women, or to those in a serodiscordant relationship (23,47). Since July 2016, every 
person diagnosed with HIV in Kenya is now being initiated ART (1,22,53). 
http://etd.uwc.ac.za/
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2.2.1 Choice of ART 
A cross-sectional study conducted in Cameroon (54) confirmed that quality pre-qualified 
antiretroviral drugs (ARVs) that meet international standards, and that are effective are given 
to patients. Similarly, there is evidence of good practice in packaging and supply of ARVs 
(49) with a combination of three or more antiretroviral regimens used. By selecting a 
combination of nucleoside analogue, reverse transcriptase inhibitors (NRTI) and one non-
nucleoside analogue reverse transcriptase inhibitor (NNRTI) and/or protease inhibitor (PI) or 
integrase inhibitor (INI), highly active antiretroviral therapy (HAART) which has been in use 
since the mid-1990s to manage HIV infections is achieved (54–56). HAART is also referred 
to as combination antiretroviral therapy (cART) (57–59). 
The use of  ART in Kenya has continually changed in line with the World Health 
Organization (WHO) recommendations, and the country readiness to adopt and implement 
new findings and interventions for HIV prevention, care, and treatment has been good (52). 
For instance, in 2009, in Kenya “55% of adults (15-year old and above) were on stavudine 
(D4T), lamivudine (3TC) and nevirapine (NVP) combination i.e. D4T/3TC/NVP. 17.1% were 
on zidovudine (AZT), 3TC and NVP. 12% on D4T/3TC and efavirenz (EFV) i.e. 
D4T/3TC/EFV. 9.2% on AZT/3TC/EFV, 3.6% on tenofovir (TDF) and 3TC/NVP i.e. 
TDF/3TC/NVP, 2.5% were on TDF/3TC/EFV while the rest of adults, mainly prevention of 
mother to child transmission of HIV patients were on non-standard dual therapy 3TC/AZT” (34).  
Over the years, the proportion of PLWH initiated on various ART regimes in resource-limited 
settings has changed remarkably because of changing evidence and HIV financing (1,52,59). 
Nevertheless, Kenya has kept pace with WHO recommendations for changes in ART guidelines 
(14). The preferred ARV regime in Kenya as at 2011 was TDF/3TC/EFV with NVP substituting 
EFV in alternative regimes and/or AZT for TDF since the fourth Kenyan ART guideline was 
rolled out (60,61). However, the choice of ART drug at initiation sometimes does not change as 
http://etd.uwc.ac.za/
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fast despite new evidence. For instance (48,52), D4T based regimen was phased out due to 
adverse drug events in 2006, but six years later, the median percentage of patients initiated on 
D4T-based regimen in two facilities in Kenya and Uganda was 7% (IQR: 3%-17%) and 0% 
(IQR: 0%-2%) respectively, and 4% (IQR: 2%-9%) for Zambia in 2010-2011. D4T was phased-
out due to its toxicities such as lactic acidosis, lipodystrophy and peripheral neuropathy 
negatively affecting the quality of life (52,62). 
Also, factors such as the cost of therapy have been shown to influence the availability and hence 
the choice of ART. In 2010, the Clinton Health Access Initiative expressed that AZT based and 
TDF based regimes were about 80% and 250% more costly than D4T based regimen annually 
(63). The cost of AZT and TDF based regimes progressively went down to four and five-fold 
for AZT and TDF based regimes in 2014 (64). ART optimization is on the rise and private 
facilities were found to be more likely to prescribe TDF-based regimes in Uganda, unlike AZT-
based regimes which were preferred in public facilities citing lack of explicit national guidelines 
and policy statements on TDF (65), especially, where clients required drug substitution.  
In a study in Uganda, the odds of a client with a baseline WHO stage IV was more than twice 
the odds of a client not being initiated a TDF-based therapy as opposed to those classified as 
stage I at initiation (52). Nearly 11% of patients in a cohort study conducted in Abidjan 
experienced ART stock outs (66) necessitating ART discontinuation or substitution. The 
discontinuation of ART regimen increases the risk of interrupting care or death for nearly three-
fold compared to those retained on ART (AHR 2.83; 95% CI, 1.25 – 6.44) (66–68). High ART 
workloads, staffing levels, and competencies have also been shown to influence the choice of 
ART initiated to PLWH (69).  Facilities with doctors were more likely to initiate a TDF-based 
therapy in Uganda (OR: 2.86; 95% CI: 1.48-5.51) (52). Moreover, clients with co-infections 
such as tuberculosis are more likely to be initiated EFV-based therapy compared to those with 
hepatitis TDF-based regimes.  On the other hand, pregnant women were more likely to be 
http://etd.uwc.ac.za/
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initiated on NVP based regimes (60). 
2.3 Monitoring HIV Specific Response on ART 
Clinical assessment and laboratory markers are used to monitor the progress of HIV infection 
(70). Clinical monitoring involves using the WHO staging system in which HIV infection is 
classified based on the presence of related signs and symptoms ibid. Initiation and monitoring 
of progress on ART have principally relied on clinical (WHO staging) and immunological 
(i.e. CD4 county) evaluations (48). In 2010, the WHO recommended the use of viral load 
(VL) monitoring every 6 months to assess viraemia and to confirm suspected ART treatment 
failure (virological failure) (7). Since 2013, VL has been considered the preferred monitoring 
and diagnosis approach (22,61) globally (WHO, 2013).  
2.3.1 Clinical Monitoring of Clients on ART 
Clinical response to first-line ART is evidenced by the absence of WHO stage three or 
four opportunistic infections (OIs) together with a reduction of papular pruritic eruptions at 
least six months after starting ART (20). The WHO HIV Clinical staging has been 
phenomenal in monitoring HIV infections in resource-limited settings since it does not 
carry any additional cost implications but has been shown to have low sensitivity in 
identifying treatment failure (71,72). WHO stage 3 represents advanced HIV while stage 4 
represents acquired immunodeficiency syndrome (AIDS) (72).  
WHO stage 3 conditions include unexplained weight loss (over 10% of presumed or 
measured body weight), unexplained chronic gastrointestinal, respiratory, oral, and 
urogenital infections as well as atypical central nervous system infections among others 
(60). WHO stage 4 conditions include HIV wasting syndrome, extensive and non-common 
infections, malignancies and disorders of the central nervous system following HIV infection 
ibid. WHO stage 2 comprises none of the severe bacterial infections of the skin and upper 
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respiratory infections (7,48,53); WHO stage 1 PLWH will typically have no symptom except 
for lymphadenopathy. WHO staging is done each time a client visits an ART clinic (18). 
2.3.2 Laboratory Monitoring of Clients on ART 
In resource-constrained settings like Sub- Saharan Africa and India, treatment efficacy was 
typically monitored through CD4+ T cell count, (7) conducted every 3-6 months to track 
HIV disease progression (73,74). Not until 2016, treatment guidelines for resource- rich 
settings principally recommended VL monitoring every 3–6 months (1,6,47). In Kenya, 
CD4 monitoring was recommended at the start of ART and every six months 
thereafter (60). Targeted VL monitoring was recommended in case of suspected clinical or 
immunological treatment failure; otherwise, PLWH would have a VL test done prior to 
initiating ART, six months later and thereafter yearly ibid. Targeted VL monitoring was 
pegged on the scarcity of funding particularly of international origin as in Kenya, over 50% 
of funds used to fight HIV are international (75).  
However, with changes in ART guidelines in Kenya in 2016, HIV specific laboratory 
monitoring calls for CD4 cell counts at the start of ART and subsequently only in instances 
of suspected treatment failure (15,18,43). Similarly, PLWH recording CD4 cell counts less 
than or equal to 100 cells / mm3 should do a serum cryptococcal antigen test (sCRAG) to 
diagnose or exclude Cryptococcus meningitis (CM) prior to starting ART (15,47). Clients on 
CM prophylaxis should have CD4 testing semiannually until they achieve greater than 100 
cells/mm3 on two consecutive occasions six months apart ibid. VL monitoring, an HIV type 1 
ribonucleic acid (HIV-1 RNA) test recommendation continues to be at the initiation of ART, 
then six months later and yearly should the client report less than 1000 copies/ml (47,60). 
2.4 Response to ART 
The efficacy of ART is paramount to the effective management of HIV infection (13,57). 
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While the combination of ART regimes have been proven effective in developed countries, the 
effectiveness of prolonged ART is not homogeneous in developing countries, probably due to 
rampant suboptimal adherence, different HIV strains and drug-resistant strains 
(10,24,25,59,76).  
2.4.1 Clinical Response to ART 
Substantial reduction in the risk of new opportunistic infections and in mortality has been 
documented following ART (13,39,58,77). However, without ART, HIV infection attacks 
the immunity increasing vulnerability to OIs (31,78). Many studies have documented a 
marked reduction in mortality and morbidity among PLWH initiated on ART, especially, in 
the first year of therapy (13,31,35,79,80). A meta-regression analysis on these studies by Low 
and team revealed the greatest reduction of OIs in oral candidiasis, cerebral toxoplasmosis 
and pneumocystis pneumonia (PCP); and, equivocal response with cryptococcal meningitis, 
herpes zoster, Kaposi sarcoma, esophageal candidiasis, and genital ulcer disease (13).  
The risk of unspecified tuberculosis (TB) decreased by over 55%, by 38% for pulmonary TB, 
and by 43% for extra-pulmonary TB on initiating ART (13,81,82). However, in a prospective 
cohort study, oral fungal infections were observed to quickly resolve with cART unlike oral 
hairy leukoplakia; enlarged parotid glands, melanotic hyperpigmentation, and oral Kaposi 
sarcoma were more persistent and slowly responded to ART (83); no improvement was 
reported in the five months of follow up for linear gingival erythema. Emergence or 
persistence of WHO stages 3 or 4 clinical conditions, and/or papular pruritic eruptions at least 
six months after initiating ART suggests treatment failure (20,37,84,85).  
2.4.2 Immunological Response to ART 
Without censoring the progression of HIV infection, depending on the viral load, CD4 cell 
count will usually decline at a rate ranging between 30 and 100 cells / µl per year, increasing 
the person’s susceptibility to OIs, and mortality (70,86–88). According to several clinical 
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trials and cohort studies, CD4 count is used for assessing immunologic response to ART and 
in deciding if OI prophylaxis can be discontinued (89). In a prospective study conducted in 
Nigeria (90), out of 113 PLWH, 105 clients had substantially higher CD4 counts than 
pretreatment level (p < 0.001); the remaining 8 clients had their CD4 counts reducing or 
remaining the same post ART initiation.  
CD4 response in the first 3 – 4 months of initiating combined ART is expected to 
increase with viral load suppression of 30 – 70/mm3 in the first 4 months, then 100 – 
150/mm
3 
per year (91,92).  The total increase in CD4 count is often limited to 300 – 
400/mm
3 
above nadir (20). Similar findings were observed in a Swiss cohort study in 
which a rise in CD4 counts of between 50 and 150 cells / mm3 was recorded in the first year 
of therapy and beyond until a steady level was reached; the highest rise in CD4 cell counts 
was noted in the first three months of therapy (73). 
2.4.3 Virological Response to ART 
Initial infection with HIV results in a rapid rise in the levels of the viral load usually greater 
than 100, 000 copies/ml; which declines after 3 to 6 months after the primary infection and 
maintains a steady state thereafter (93,94). In a cohort initiated ART, HIV viraemia reduced to 
1.8 log copies/ml (10,58) within 3 months of therapy. Complete viral suppression in patients 
on ART results in immunological response evidenced by an increase in CD4+ T-cell 
count. Furthermore, early and good immunological response to antiretroviral therapy 
portends good clinical outcomes (19,20,26,85,95).  
Viral load monitoring is a critical test for ART treatment response (96). Meta-analyses of 
clinical trials revealed that the least significant rise in VL was three-fold although the 
optimal response to ART is persistent once a patient reaches undetectable VL levels (97). 
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However, it is not uncommon to find successfully treated patients with viral blips 
(transient detectable viral loads) (97–99) which have an unsettled role in predicting 
virologic failure. Individuals without resistance strains of HIV who have been adherent to 
their ART regime should achieve viral suppression within 8 to 24 weeks of initiating 
therapy (20,22,30,100). In contrast (101), clients with baseline viral loads greater than 
100, 000 copies/ml may have a slower rate of viral suppression. 
2.5 Treatment Failure 
Treatment failure is the progression of HIV disease despite using ART for at least six 
months. Therapy failure is demonstrated clinically as emergence or recurrence of WHO 
stage 3 or 4 and/or papular pruritic eruptions; or immunologic with CD4 cell count 
dropping or not responding appropriately; or virologic rebound with detectable viral load 
(6,31,35). The concern with ART failure is that it leads to switching to more costly regimes 
(102). Hence, the decision on when to switch from first to second-line therapy continues 
to be a critical step i n  ART management; however, as programs evolve, evidence change 
and more patients continue on ART (15,29,103). These failures (clinical, immunological or 
virological) may occur in isolation or in combination due to poor ART adherence, or sub-
optimal ART dosing over a duration of time resulting in a cascade of viral failure followed 
by an immunological lack of response to therapy and finally, clinical manifestations of 
AIDS-related illnesses (6,20,28,54,104).  
2.6.1 Criteria for Identifying ART Failure 
WHO recommends clinical and immunological criteria for monitoring ART failure 
(37,60,102). Criteria for screening ART failure includes clinical, immunological and 
virological markers administered to patients who have been on therapy for at least 6 
months (105). Clinical failure is defined by the emergence of new or recurrent WHO stage 3 
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or 4 conditions or pruritic papular eruptions; while immunological failure is characterized by 
a drop in CD4 cell count or percentage in baseline levels or a decline of more than 30% in 
CD4 count or percentage (29,60). In patients who have received more than 12 months of 
ART, immunological failure may be CD4 count increase < 51 CD4 cells/µl or CD4 cell 
counts that persistently remain below 100 cells/µl on the other hand, VL above 1000 at least 
six months after initiating ART is considered virological failure (102,105).  
However, monitoring failure immunologically and clinically has been shown not to 
provide accurate results. For this reason, VL monitoring is recommended as the preferred 
approach (6,61,84,85,102). VL monitoring differentiates treatment failure from non-
adherence to therapy hence its use as a determinant for assessing the risk of HIV 
transmission in the populations (32,61,106). In contrast, a trial comparing the utilization 
of VL monitoring with the criteria for ART failure did not show any difference in 
mortality, the incidence of clinical failures, switching to second-line or presence of drug 
resistance (107). 
2.6.2 Factors Associated with ART Treatment Failure 
There are determinants that influence how long viral suppression could be sustained. 
2.6.2.1 Virus Related Factors 
Variations in the HIV genome have been associated with varied rates of HIV progression 
(89). HIV variants with a deleted nef gene show a slow progression while HIV strains (the 
X4 virus also called the syncytia-inducing virus) that use CXCR4 proteins as entry co-
receptors progress rapidly ibid. Drug-resistant mutations affect the efficiency of virus 
replication (viral fitness) with those with decreased viral fitness having slower 
immunodeficiency than the wild-type (20,89). Similarly, clients with HIV type 1 infections 
progress faster than those with type 2 (74,91). Clients with a high baseline viral load greater 
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than 1 million copies/ml have increased chances of failure (108). On the other hand, patients 
starting therapy with a low detectable viral load below 1000 copies/ml may have notable 
‘return to mean’ episodes also referred to as virologic blips nonrelated to adherence 
problems or resistance to therapy (98,99) which is of limited clinical significance.   
2.6.2.2 Drug-Related Factors 
In a Canadian cohort study, drug resistance was detected in 25% of clients on cART (93). In 
the Canadian study, like several other studies, drug resistance (DR) mutations were 
common in clients who started therapy with high baseline plasma viral loads; or, had prior 
exposure to NNRTIs (multivariate HR 1.84, p=.001) (26,93,106,109). Similarly, in a case-
control study conducted in South Africa, treatment interruption due to non-adherence 
increased the odds of failure 8 times and increased 9 times in those who used NVP based 
PMTCT regimen (110).  
Certain ART regimes are associated with high side-effects and toxicities and have recorded 
high rates of discontinuation or regimen switching these include NVP-based therapy at 
60.7% and D4T based regimes at 39.3%. However, 3TC has been found to be well tolerated 
with no toxicities (111). Buck established that the average time for switching to first-line 
was 2 months and 16 months for second-line regimes. Furthermore, patients on didanosine-
based therapy failed more than those on 3TC-based regimes (112). Among ART-
experienced patients with treatment failure, NNRTI resistance mutations 184V were seen in 
62.3% of patients; 103N in 48.1%; 190 A/S in 11.7%; and, L90M in 11.7% (9,113). A 
sizeable 12% of those who failed therapy had thymidine analogue mutations (TAMs) but 
only 1% had more than 1 TAM; conferring a 95% chance of treatment success among naïve 
clients on ART compared to 84% in experienced patients (113). 
Regimen potency has been identified as an important factor for treatment success 
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(20,114,115). Boosted protease inhibitor and non-nucleoside reverse transcriptase inhibitor 
(NNRTI) containing ART were shown to have the highest potency of 64% compared to 
nucleoside reverse transcriptase inhibitors (NRTIs) and non-boosted protease inhibitors at 
54% and 43% respectively with viral load < 50 copies /ml (20).  CD4 increase was highest 
with protease inhibitors followed by NNRTIs and eventually NRTIs (20,115). The highest 
risk of resistance to a PI-based regimen is with virologic failure in the face of good 
adherence (20). 
Bartlett and Gallant conducted a systematic review of literature and conference 
presentations of clinical trials on treatment-naive patients from 1994 to July 2006. The two 
researchers covered 53 trials and sampled 14,264 participants. The percentage of patients 
who achieved a viral load < 50 copies/ml at 48 weeks increased with time and by ARV 
drug and class. In 1998, viral load increased to 41%; to 50% in the year 1999–2000, to 
56% in 2001-2002 and, to 64% in 2003-2004. Increases in viral load and CD4 count 
NNRTI containing regimes was 64% and 173 copies/µl respectively. Boosted PIs with 
ritonavir (PI/r) was 64% and 200 copies/µl; while those who were on triple NRTIs 
reported 54% and 161 copies/µl; and, those on unboosted P I s  had 43% increase in viral 
load and 179 copies/µl of CD4 cells.  Those on boosted PIs i.e. PI/r combination had 
statistically significant (P<0.05) better immunological response.   
Finally, particular drug-drug and drug-food interaction have been shown to negate the effect 
of ART by inhibiting the optimal response of some ART components. The use of 
antifungals like ketoconazole together with nevirapine inhibit liver action, thus increasing 
adverse reactions and reducing the active components of the drugs (12,20,116).  
2.6.2.3 Host-Related Factors 
Adherence to ART of greater than 95% to the prescribed doses contributes to at least 80% 
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probability of viral suppression at 24 weeks on ART (18,91,117); poor adherence predicts 
virologic failure but not necessarily resistance to ART (118). However, imperfect adherence 
as has been seen in drug holidays are a threat to treatment success leading to treatment 
failure and consequently drug resistance because drug concentrations fall within a mutation-
selection window or sub-optimal levels allowing the replication of the virus in the wake of 
therapy (119).  
A retrospective cohort study conducted in Ethiopia found that treatment failure was more 
likely to occur in PLWH with poor adherence and those who delayed starting ART until 
their CD4 count was lower than 100 cells / mm3 (35). Young age and the presence of an 
active WHO stage 3 or 4 OI such as tuberculosis increased the likelihood of failure (28). A 
cross-sectional study in Colombia established that advanced HIV disease and CD4 cell 
count below 200 cells/mm3 were associated with primary resistance to ART, p=0.0040 
respectively (113). Patients beginning ART with very low CD4 counts (≤200 cell/mm3) or 
elderly patients tend to have a poor increase in their CD4 counts despite achieving viral 
suppression (91,120). 
Substance abuse such as excessive alcohol intake among PLWH on ART is a contributor to 
non-adherence (12,121). Patients hazardously abusing a substance, are at risk of scaffolded 
or ‘triply’ conditions of HIV and psychiatric comorbidities (122). Community peer support, 
a good physician-client relationship, and similar social support such as from family 
members, has a positive effect on viral suppression (11,76). Conversely, some cultural 
predispositions and family circumstances have been found to affect the attitudes of clients 
towards ART and their adherence (45). Choosing not to disclose was found to be a coping 
mechanism and was not necessarily linked to adverse psychological effects or treatment 
success (17). Children and adolescents undergoing enhanced adherence counseling (EAC) 
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were seen to achieve better viral suppression (10). 
In a retrospective cohort conducted in Thailand, adherence below 95% and clients below 
the age of 40 years were independent predictors for virologic failure among clients on ART 
(85). However, in a cohort study conducted in Kenya, HIV infected patients older than 64 
years of age were more likely to die and had faster disease progression due to a less robust 
CD4 cell response to ART and higher non-AIDS related morbidities (123) compared to the 
youth aged between 15 and 24 years. The survival time for the elderly patients in the Kenya 
study was 5.0, [95% CI (4.0 – 6.2)] and for the youth 11.0, [95% CI (10.7 – 11.7)] 
respectively; no difference was reported between males and females. In an exploratory 
descriptive study done in Peru (116), virologic failure was recorded at a median age of 35 
years. 
PLWH with high interleukin 6 (IL-6) and D-dimer have been shown to progress faster and 
even die earlier due to end-organ damage that does not seem to return to normal even with 
ART (89). Various human leukocyte antigen alleles appear to determine rates of viral 
progression with individuals with CCR5 variants having a slower progression of HIV (60). 
Malnutrition, especially among children,  reduces the bioavailability of certain drugs like 
EFV and LPV and increases NVP (124). Reduced bioavailability of drugs decreases their 
efficacy, while toxicity and side effects are associated with an increased bioavailability ibid. 
Finally, viral blips, severe immunological status (such as very low CD4 counts at baseline) 
and immunological discordancy (in which the client’s CD4 are non-responsive in the 
presence of good virological and clinical picture) are also critical precursors of poor 
treatment response (22,104,125). In a Swiss cohort study, 71% change of ART regimen was 
in clients with low CD4 counts (baseline median of 105 cells/ml) and in those with follow-
up CD4 counts below 201 cells/ml; a significant 8% change in ART regimen was noted to 
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occur within the first 12 weeks of starting therapy (30). Globally, between 20% and 40% of 
clients initiating ART have a discordant response to therapy (126). Unlike clients with 
concordant response to therapy, discordant responses 3 to 9 months after initiation of ART 
was associated with a short time to an OI or death (104,126).  
2.7 Retention of Clients on ART 
In a systematic review and meta-analysis conducted in low and middle-income countries, 
78%, 71%, and 69% of patients were retained on therapy at 12, 24, and 36 months following 
initiation of ART (127). A large number of studies in Sub-Saharan Africa have identified 
high attrition on ART (128–130). PLWH not retained on ART will often be among those who 
die, stop follow up or discontinue ART or self-transfer to other programs (131). Attrition is 
happening notwithstanding knowledge that the greatest impacts of ART accrue with lifelong 
uninterrupted adherence to therapy, without which treatment failure ensues, drug resistance 
emerges, and there is an increase in morbidity and mortality (132). 
Attrition of clients on ART is the loss of these patients from the ART program; whereas 
retention on ART regards patients staying alive on therapy and active on follow up at the 
ART clinic (84). ART attrition is a function of patients on ART dying, becoming lost to 
follow up or discontinuing ART, including transfer outs in attrition and giving a crude status 
ibid; lost to follow up is defined as a client not honouring their ARV pick up for more than 90 
days (84,133). High attrition rates are associated with high rates of ART failure (134,135). 
Possible predictors of attrition on ART include high costs incurred by patients to get care, 
unacceptable models for ART provision, extremes CD4 counts, male patients, and adverse 
drug events (18,71,85,129,136).  
The ability to retain patients for treatment remains limited (84). For instance, African ART 
programs reported, on average, higher failure and attrition rates than Latin American and 
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Asian programs in 2014 despite the need for these programs to ensure that at least 90% of “all 
people diagnosed with HIV infection receive sustained ART” and are retained in the 
program by the year 2020 (23). Pressing evidence points to the need to optimize ART goals 
by relooking and fostering aspects that identify HIV positive clients and get them referred 
and enrolled in an HIV clinic (linkage), engaging and consistently following them up 
(retention), as well as providing comprehensive and integrated services (137,138). However, 
HIV is recognized as a single but complex infection with a multitude of potential socio-
economic factors that should be sought after and addressed to minimize disparities in 
retention occasioned by limited health insurance; stigma, violence and gender disparities, 
difficulties and challenges due to geographic location, steep gradients in health literacy, 
unemployment, poverty and loss of income (130,133). 
2.8. Conceptual Framework for the Present Study 
Initiating ART among HIV infected patients coupled with optimal adherence to therapy 
results in a decrease in viral load and a concurrent increase in CD4 counts, a reduction in OIs 
and improved quality of life. Good response to ART is thus associated with prolonged life 
and maintained therapy options (Figure 1); such a patient is said to have ART treatment 
success. On the contrary, the patients who continue to experience an increase in VL, a drop in 
CD4 counts, have recurrent and/or emergent OIs after at least six months of ART are said to 
fail therapy. Patients failing ART will experience deteriorating health, will often require a 
change of their regime and are more likely to die. Hence, poor ART treatment outcomes are 
as a result of therapy failure.  
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2.8   Present Study’s Conceptual Framework 
 
 
  
Increased Viral Load 
Diminished CD4 count 
Multiple OIs 
Increased mortality 
Initiate ARV 
Viral Load increases 
CD4 count decreases 
OI increase → Dominate 
Gain loss 
Attrition on ART 
Sick / Die 
Change ART → 
Diminished options 
 
Viral Load diminishes 
CD4 count increases 
OI diminish → 
Eliminated 
Gain weight 
Alive and well 
Retained on ART 
Maintain ART options 
Improved 
adherence 
Poor 
adherence  
Resistance 
Treatment Failure Treatment Success 
Yes Yes 
No 
Figure 1. Conceptual Framework for Assessing ART Treatment Outcomes 
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CHAPTER THREE 
METHODOLOGY 
3.1 Study Design 
This was a retrospective cohort study based on a retrospective review of patient clinical 
care and treatment data at Kakamega County General Hospital (KCGH) from July 2014 to 
June 2015. The researcher was able to follow up a group of clients back in time from the 
time they initiated ART until they became lost to follow-up, died or the observation 
period concluded in August 2017, whichever occurred first,  to determine the causes of 
poor treatment outcome – clinical, immunologic and virologic failure, estimate incidence 
and the risk of attrition – a loss to follow-up and mortality for an accurate measurement of 
exposure variables.  
3.2 Study Population 
A retrospective clinical record review was conducted for clients aged 15 years and above 
initiated on first-line ART between July 2014 and June 2015 and on follow up at 
Kakamega County General Hospital (KCGH) Comprehensive Care Clinic (CCC). KCGH 
being a county referral hospital based in Kakamega Central (Appendix I), the study 
population were adults drawn from both its primary and secondary catchment populations.  
3.3 Inclusion and Exclusion Criteria 
Inclusion criteria - To be included in this study, clients must have been initiated on ART 
between July 2014 and June 2015 in the CCC at KCGH, aged 15 years and above; whose 
clinic information was available; and, had been on ART two to three years at the 
commencement of the study. These clients started on a standard first-line ART regimen 
according to the national ART guidelines of 2011.  
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Exclusion criteria – All clients at KCGH CCC started ART more than three years or less 
than two years before the commencement of the study; those initiated on ART elsewhere 
other than at KCGH and those initiated on nonstandard first-line ART regimen according to 
national ART guidelines; those not on ART and clients aged below 15 years.  
3.4 Sampling 
This study used data from the enrollment and follow up databases at KCGH CCC. The 
electronic medical record was matched with client files and clinic registers. Of 548 adult 
client records accessed, 37 records had wrongfully indicated their age and so were 
excluded; 82 records had the wrong ART start date; 7 records were found to be duplicates 
and 174 records were incomplete, missing key study variables such as ART regimen, 
WHO clinical stages, CD4 counts, viral load results and follow up information. All the 
remaining 284 records were therefore selected for the study as shown in figure 3.1 below. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 Flow chart of the records that were accessed and included in the study 
Kenya Open MRS 
(electronic medical 
records) had 584 
records 
Daily ART Activity 
Register and patient 
files found 580 records 
7 duplicates in 
EMR excluded 
577 records 
successfully 
linked 
174 records excluded 
for missing key 
variables 
284 records included 
and taken for the study 
37 records with 
wrong age excluded 
82 records in wrong 
cohort excluded 
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3.5 Data collection 
A quantitative method relying on secondary data was used. Data were obtained from 
routine patient records in the ART clinic at KCGH. Patients enrolling and starting ART 
had their details first captured in patient files on the medical and follow up cards, and the 
Daily ART Register which is a cohort register capturing client information based on year 
and month of starting ART. Patient information was recorded in the clinic files then 
routinely updated in the electronic medical records (EMR) called Kenya Open MRS by 
data officers employed by the clinic. A list of unique identifier numbers was generated by 
the data officers based at the clinic. The research compared the details of the unique 
identifier number list and those in the ART cohort register. Clients whose ART start dates 
occurred between July 2014 and June 2015 were identified and their clinic records 
retrieved. Key variables on client demographics, age, gender, and medical information 
such as the presence of opportunistic infections, CD4 level, WHO staging, viral load 
results, ART regimen and follow-up status in the clinic were collected from the files by the 
researcher through a chart abstraction tool (Appendix II). The researcher then transferred 
the details of each patient’s information from the chart abstraction tool to an Access 
database from where data was then cleaned and final records and variables picked for 
analysis. 
3.6   Data Analysis 
Outcome measures for this study were: opportunistic infections (OIs), WHO staging, CD4 
counts, virological suppression and loss to follow up (LTFU). The information entered in 
the EMR was obtained and exported to an excel spreadsheet. It was cleaned by cross-
checking it with information in patient files and the daily ART activity register and then 
imported into Access database, from where it was imported into STATA 15.1 for analysis.   
The analysis for descriptive statistics was done using frequency and relative frequencies to 
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determine trends in categorical data (such as age group, ART regimen) while measures of 
central tendency and dispersion i.e. mean, standard deviation, median and interquartile 
range were determined for continuous data such as age, CD4 and VL counts were 
compared by gender. Immunological and virological outcomes were assessed by 
calculating and plotting median CD4, viral load and months on ART. Clinical outcomes 
were assessed by comparing the proportions of those who had OIs and WHO stages III and 
IV at 0, 6, 12, 18 and 24 months of initiating ART. ART follow up status was analyzed 
based on follow up status at the time of conducting the study. Bivariate data analysis was 
done to assess the relationships between the variables for each study outcome using T-tests 
for continuous variables and chi-square for categorical variables.  
Three models were fitted with CD4 and VL as response variables. Multivariate modeling 
for random effects that could account for intra- and inter-subject variations and demonstrate 
factors associated with the outcomes of interest at least after six months of ART were 
conducted were considered. Mixed models allow a flexible approach to modeling 
longitudinal and hierarchical data; and, they handle non-homogeneous data points for 
subjects observed at different time points (139). Variables in this study were defined at the 
5% significance level but a continuous scale of effect size estimation was utilized. 
Different from the traditional approach in which significance is strictly considered at 5% 
significance, this study considered value between 5% and 10% to be marginal. 
Survival time (time from start of ART to death) and the hazard of getting lost were 
evaluated by Kaplan-Meier survival analysis and multivariate Cox proportional hazards 
modeling. Variables that were significantly associated with events occurring in univariate 
analysis at a p=0.02 level were those included for evaluation in multivariate modeling. 
Only those that retained significance p<0.05 in the multivariate model were further 
included in the final model. Potential independent predictor variables were evaluated for 
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collinearity by examining non-parametric rank correlation coefficients (such as Spearman 
correlation coefficient) and a variety of models tested and compared using the -2log 
likelihood measures for the goodness of fit. Clients who were LTFU were censored as of 
the last date of the clinic visit, 90 days after their last clinic date. 
3.7   Validity and Reliability of Chart Abstraction Tool 
The variables in the chart abstraction tool (Appendix II) were national standards of care 
similar to WHO recommendations (1,15). Clinical, immunological, virological and retention 
were treated as time-varying covariates. Virological failure was set at 1000 copies/ml while 
treatment failure was aligned to WHO criteria for screening therapy failure using clinical and 
immunological elements (29,60). The chart abstraction instrument was adopted from a 
current ART program. 
Reliability was ensured by collecting data from both patient files and cross-examining with 
the existing electronic medical records available in the hospital. The chart abstraction tool 
was checked for chronology and construct by the study supervisor. Data obtained was 
cleaned and validated. Out of range data was confirmed on site during the study period. The 
hierarchical model used was adjusted for missing values in the analysis panels. Confounders 
such as age and sex were considered a priori and examined.  
3.8    Ethical Considerations 
Study participants: This study’s proposal was submitted and received ethical clearance 
from the University of the Western Cape (BM17/1/11), and in Kenya through the guidance 
of National Commission of Science Technology and Innovations obtained ethical 
clearance at Maseno University (TT17200R) and the hospital – Appendix III. 
Patient-level information: such as names, phone number, clinic identification numbers, 
physical locator information were removed and a database unique identification number 
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assigned. 
Benefits: Future clients at the clinic are bound to receive improved ART care and 
treatment services following the results of this study. 
Informed consent: Secondary data was used, and some patients included in the study had 
already left the clinic or died; however, the hospital granted permission to use the ART 
clinic data in this study. 
Confidentiality: Only staff at the health records office in the ART clinic could access the 
database for this study which was password protected and saved on a password-protected 
computer in their office. Furthermore, no patient will be identified when the results of this 
study are presented.  
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CHAPTER FOUR 
RESULTS 
4.1. Social Demographic Characteristics 
The study enrolled 284 HIV infected adult patients comprising 96 males and 188 females 
starting ART at Kakamega CGH between July 2014 and March 2015. Follow up was done 
from the start of ART to the end of August 2017 through retrospective review of patient 
records captured in the electronic medical records. Except for age, baseline WHO stage and 
baseline OIs, both males and females had similar baseline characteristics (Table 1). The 
difference in age categories was marginal, p=0.0060.  
 
Table 1: Baseline Characteristics of Study Participants Starting ART 
Characteristics Male (n=96) Female (n=188) p-value 
Age mean (SD) 39.9 (10.2) 35.7 (10.7) 0.0019 
Youths (15 – 35 years old), % 37.5% 56.9% 0.0060 
Married, % 40.6% 51.1% 0.5460 
Days to ART from enrollment, mean (SD) 611.5 (893.4) 616.0 (756.0) 0.9644 
Weight mean (SD) 60.5 (9.5) 61.0 (9.5) 0.6614 
Advanced disease WHO stage (3&4), % 47.9% 28.2% 0.0100 
CD4, mean (SD) 226.5 (121.1) 245.6 (125.9) 0.2369 
Not disclosed, % 13.5% 15.4% 0.6720 
 
There were 50.4% (143) youths (aged 15 to 35 years) in the study, compared to 42.6% (121) 
middle-aged patients (aged 36 to 54 years). Those older than 54 years were considered 
elderly. Among the youths, 56.9% were females.  
4.2. Antiretroviral Therapy 
The median time to initiating ART upon enrolment into care was 4.3 months. Female patients 
took thrice the median time to initiate therapy compared to males, 5.7 and 1.9 respectively; 
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however, the average time to ART by sex was similar, p=0.9646. There was an association 
between the type of regimen initiated and age group, p=0.0090 but none between regimen 
initiated and the sex of the participants, p=0.7350.  
 
Table 2: ART initiated to Study Participants 
Age Group Youth (n, %) Mid Age (n, %) Elderly (n, %) Total (N, %) 
3TC+ABC+EFV 0 (0.0%) 0 (0.0%) 1 (5%) 1 (0.4%) 
3TC+EFV+AZT 2 (1.4%) 0 (0.0%) 0 (0.0%) 2 (0.7%) 
3TC+D4T+NVP 5 (3.5%) 5 (4.1%) 0 (0.0%) 10 (3.5%) 
3TC+AZT+EFV 8 (5.6%) 8 (6.6%) 1 (5.0%) 17 (6.0%) 
3TC+AZT+NVP 11 (7.7%) 22 (18.2%) 2 (10.0%) 35 (12.3%) 
3TC+NVP+TDF 41 (28.7%) 24 (19.8%) 8 (40.0%) 73 (25.7%) 
3TC+EFV+TDF 76 (53.2%) 62 (51.2%) 8 (40.0%) 146 (51.4%) 
Total (N) 143 121 20 284 
The proportion of patients initiated on a TDF based regimen was 77.5% (this includes the 
patient initiated on an ABC based regimen), while 19.0% were on an AZT based regimen, 
and the rest were started on a D4T based regimen (Table 2). A higher proportion of the 
youths (81.8%) was initiated on a TDF based regimen compared to the rest of the age 
categories 72.3%. Among 93.3% of patients, ART was initiated based on a CD4 count less 
than 501 cells/mm3, the rest were due to advanced HIV disease qualified as either WHO stage 
3 or 4. 
4.3. Study Outcomes 
4.3.1. Clinical Outcomes 
2.5.1 4.3.1.1. Weight 
Baseline mean and median weights for study participants were similar, 60.8 ±9.5 and 60.7 
(IQR 54.0 to 66.2) respectively, and did not differ by sex, p=0.6614. The baseline median 
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weight for male patients was 60.5 kg (IQR: 52.9 to 65.9) and 61.0 kg (IQR: 54.3 to 67.0) for 
female patients. Weight gain peaked at one year of ART with a median of 62.0 kg (IQR: 55.0 
to 67.0), where male patients recorded 62.0 kg (IQR: 55.0 to 65.5) and females 61.1 kg (IQR: 
55.4 to 67.3) (Figure 2).  
 
Figure 2: Box Plot for Median Weight Trends by Gender 
 
Among those patients who lost weight, 60.0% (9) were female patients, 66.7% (10) were 
middle-aged patients followed by 26.7% (4) the youths; while only 6.7% of those who lost 
weight were required to change therapy, and 13.3% of those who lost weight died.  
2.5.2 4.3.1.2. Opportunistic Infections 
Among patients starting ART, 69.0% did not have an OI. Overall among the 31% patients 
that had an OI, 23.2% had advanced disease opportunistic infections at baseline. 7.0% 
patients had TB/HIV co-infection, 3.2% had papular pruritic eruptions, 2.8% (8) had 
Kaposi’s sarcoma, 2.5% (7) had PCP and a similar proportion chronic diarrhea, while 2.1% 
(6) had Cryptococci meningitis. The frequency of these diseases went down at least two-fold 
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below baseline frequencies in subsequent months as patients continued ART. There was a 
statistically significant reduction in the recurrence of advanced OIs among those who had 
advanced OIs at baseline to as low as 15.1% compared to 84.9% among those who neither 
had OIs nor had advanced disease at the start of therapy, p<0.0001. Nonetheless, the 
incidence of pulmonary TB (PTB) did not go down over the study period, with at least 30.8% 
of patients on ART being diagnosed with PTB over the follow-up period. 
There was a statistically significant difference between the presence of baseline severe OIs 
and sex, p=0.0490 but this became marginally significant with therapy, p=0.0650. However, 
male patients had more episodes of recurrent advanced disease OIs at 19.8% (133 episodes) 
compared to 12.8% (168 episodes) among female patients, p<0.0001. Likewise, there was a 
statistically significant association between age group and recurrent advanced disease OIs. 
The proportion of youths with severe disease was 12.9% compared to 16.5% middle-aged 
patients, and 25.0% among elderly patients, p<0.0001.  
2.5.3 4.3.1.3. WHO Staging 
The proportion of patients with advanced WHO staging i.e. WHO 3 or 4 at baseline was 
34.9% (99) and decreased to 6.5% (18) at month six and thereafter to less than 5.1% (13). 
Males had 1.6 times more cases of advanced WHO staging at baseline, 47.9% (46), compared 
to female patients, p=0.0430; however, there was a marked reduction in the frequency of 
advanced WHO staging among the male patients at six months of ART, p=0.0280. After six 
months of follow up, the frequency of advanced WHO stage remained below 10.0% with no 
statistical difference between the sexes. Advanced WHO staging and age group were not 
associated, p=0.6230; but, 45.0% (9) of elderly patients had advanced WHO staging at 
baseline, compared to 33.9% (41) of middle-and 34.3% of youths.  
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2.5.4 4.3.1.4. Sustained ART Options 
Among patients initiating ART, 91.2% were retained on their initial ART regimen. Single-
drug substitutions were the commonest reason for changing a patient’s therapy, accounting 
for 56.0% of drug changes followed by the switch to second-line therapy at 24% due to 
patients failing ART. Some patients switched regimen because they had adverse drug 
reactions or were sharing their doses, at 8% respectively; one patient discontinued therapy 
because they did not have the financial means for their treatment. D4T phase-out was the 
main reason for single drug substitution, accounting for 85.7%; otherwise, a single ARV drug 
substitution was done to accommodate TB treatment (Table 3).  
Table 3: Reasons for Changing ART Drugs 
Therapy Change Reason Counts Percentage 
Therapy not changed 259 91.2% 
Substitution (including D4T) 12 4.2% 
Treatment failure 6 2.1% 
Adverse Reaction 3 1.1% 
Share with others 2 0.7% 
TB treatment 2 0.7% 
Total 284 100% 
 
Half of the patients who switched regimen to second-line therapy were male. Youths 
contributed 66.7% (4) of switches to second-line therapy and the rest, 33.3% (2), were 
middle-aged patients. Optimal adherence to ART (assessed as greater than 94.0% of 
adherence) as at the last patient’s ART visit was 77.1% (219), 20.8% (59) had fair adherence 
(between 90.0 and 94.0% adherence) to ART and the rest had poor adherence. Despite there 
being no association between ART regimen and age group, 82.0% of mid-aged patients had 
better adherence to ART, followed by the youths at 74.1% and the elderly at 70.0%.  
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4.3.2. Immunological Response  
Over 95% of patients who were enrolled and initiated ART at KCGH had access to CD4 
testing every six months from baseline. Males had a 97.9% insignificantly different CD4 
response compared to 96.8% of females, p=0.5934. Similarly, 97.2% of the youths initiated 
on ART, 97.5% of the middle-aged and 95.0% of elderly patients had optimal CD4 response, 
p=0.8190 There was a progressive rise in CD4 counts over time upon initiating ART (Figure 
3). Mean baseline CD4 count was 239.2 ±124.4 which rose to 301.7 ±130.5 at six months, 
375.7 ±140.0 at one year, 495.9 ±163.9 at two years and 556.8 ±179.5 at 3 years of follow up.  
 
Figure 3: Individual Patient CD4 Counts and Trend Line 
 
CD4 failure is time-varying; for each unit increase in time among patients on ART, cases of 
CD4 failure increased by 2.10, p=0.0010. Recurrent WHO stage 3 or 4 conditions, and 
pruritic papular eruptions at least six months on initiating ART was associated with 14.4 
times the likelihood of CD4 failure compared to those who had good CD4 response 
(p<0.0001). Elderly patients and those who had detectable viral load results had an 
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insignificantly increased likelihood of failing CD4, of 4.9 times compared to youths, and 0.62 
times, p=0.2550 and p=0.8240, respectively, (Table 4). Patients with a recurring advanced OI 
disease were .01 times less likely to have sub-optimal CD4 progression compared to those 
who did not have recurrent advanced OIs, p=0.9730, an insignificant finding. Middle-aged 
patients had 1.4 times fewer chances of reporting poor CD4 progression compared to youths, 
p=0.5240. Female patients were 81.3% less likely to have poor CD4 counts over time, but 
this was not statistically different from male patients, p=0.7300.  
Table 4: Table for CD4 Random Effects 
CD4 Failure Coef. Std. Err. Z P>z 95% CI 
Female -0.8131 2.3523 -0.35 0.7300 -5.4236 3.7974 
Age Group       
        Middle Age -1.4139 2.2212 -0.64 0.5240 -5.7674 2.9396 
Elderly 4.9042 4.3054 1.14 0.2550 -3.5343 13.3427 
Recurrent OI -0.1011 2.9686 -0.03 0.9730 -5.9195 5.7174 
Advanced WHO 14.4128 2.4618 5.85 0.0000 9.5877 19.2379 
Detectable VL 0.6217 2.7918 0.22 0.8240 -4.8501 6.0935 
Months on ART 2.0968 0.6087 3.44 0.0010 0.9037 3.2899 
_cons -101.8613 22.021 -4.63 0.0000 -145.0216 -58.701 
              
/lnsig2u 5.1298 0.2133     4.7117 5.5479 
sigma_u 12.9992 1.3865     10.5469 16.0216 
Rho 0.9809 0.004     0.9713 0.9873 
 
 
2.5.5 4.3.2.1. Suspected Treatment Failure 
The proportion of patients with recurring advanced disease (WHO stage 3 or 4) was 23.6% 
(67), or those with papular pruritic rash, or drop of CD4 count below baseline level, or a drop 
of CD4 count of greater than 30% of peak at least six months on initiating ART or those who 
had a drop in their weight for greater than 10% (Figure 2). Recurrent advanced disease OI 
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was the commonest cause of suspecting therapy failure with 68.7% (46). The frequency of 
patients identified to have recurrent advanced OIs did not correlate with the frequency of 
patients suspected to fail therapy based on CD4 count 11.9% (8), (r=0.0407, p=0.4947) 
(Figure 3). None of the patients was suspected for therapy failure entirely based on weight 
trend, 47.8% (32). 
There was a marginal association between patients suspected for therapy failure and sex, but 
not by age group, p=0.0990, and p=0.1450 respectively. Among those who failed, 29.4% of 
male patients were suspected of ART therapy compared to 20.1% females. Elderly patients 
contributed 43.8% of those suspected of ART failure. Relative to male patients being 
suspected for therapy failure, female patients suspected for treatment failure had an all-time 
decreased hazard of failure (HR = 0.6613) though this was not a statistically significant 
benefit, p=0.1170 (Figure 4).  
stf 
(n=67) 
wtf 
(47.8%) 
oif 
(68.7%) 
cd4f 
(11.9%) 
Whof 
(100%) 
Key: 
stf: suspected ART failure 
wtf: weight failure 
oif: OI failure 
whof: WHO failure 
cd4f: CD4 failure 
 
Figure 4: Results for Treatment Failure Based on Screening Criteria 
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Figure 5: Instantaneous Hazards for ART Failure based on Screening Criteria 
4.3.3. Virologic Response 
More than 98.5% of patients eligible for viral load monitoring received the test and the results 
were available during the study period at six months, one year, and each subsequent year of 
follow up on initiating ART. 83.0% (229) of patients on ART had undetectable viral loads in 
the study period (Figure 5). Among those who failed, the incidence rate ART 15.8% (43) was 
highest at six months of initiating and sharply diminished in the months that followed, 1.1% 
(3) at 12 months and less than 1% thereafter. Female patients with detectable viral load were 
14.8% (27), and compared with 21.5% (20) of males, p=0.5476. There was no association 
Figure 6: Individual Patient Viral Load Counts and Trend Line 
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between having a detectable viral load and age group, among those who failed therapy.  
Youths who had not disclosed their HIV status, 58.3% (7), were more likely to have 
detectable viral load at least 6 months on initiating ART compared to 33.3% (4), middle-aged 
patients, and only 8.3% (1) elderly patients on ART, p=0.8900. There was a positive 
correlation with the results of suspected treatment failure and viral load failure, detectable 
viral load counts (r=0.6047, p<0.0001). The 60.3% (35) patients on ART suspected for 
therapy failure were correctly classified as having failed therapy as confirmed by viral load 
testing (Table 5). 
Table 5: Comparison of Viral Load Results and Findings of Screening Criteria 
Status Undetectable VL Detectable VL Total 
Unsuspected TF, count (%) 172 (20.45%) 9 (75.73%) 181 
Suspected TF, count (%) 23 (79.55%) 35 (24.27%) 58 
Total 195 44 239 
Following bivariate analysis, the probability of patients on ART for at least six months 
having detectable viral loads with a baseline history of not having disclosed their HIV status 
was 69.7% higher for each patient that failed therapy compared to their counterparts who had 
disclosed, p=0.0410, while those who had a WHO stage 3 or 4 disease, were seen to be 1.66 
times more likely to have detectable viral loads compared to those with WHO stage 1 or 2 
disease, p<0.0001 (table 6). The probability that a patient would have detectable viral load 
decreased as one’s CD4 counts increased. Patients with CD4 counts of between 351 – 500 
cells/mm3 and those with greater than 500 cells/mm3 had less than 1.87 and 2.45 times, 
respectively; those who had less than 200 cells/mm3 were likely to have detectable viral 
loads, p<0.0001.  
The time a patient takes on ART was related to a reduction in the probability that such a 
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patient would have detectable viral by 3.9%, p=0.0030. Females and middle-aged patients 
were associated with a statistically insignificant reduction in the likelihood of failing therapy 
of 38.16% and 13.42, compared to males and youths respectively. Patients with suboptimal 
adherence, rated at 90 – 94%, experienced less than 14.53% likelihood of having 
undetectable viral loads compared to those with optimal adherence of > 95%, p=0.6990.  
Table 6: Variate Analysis for Viral Load Response 
Variable 
Bivariate Analysis Multivariate Analysis 
Coefficient p-value Coefficient p-value 
Gender         
Female - 0. 3867 0.1960 - 0. 3155 0. 3110 
Age group         
Middle aged (36 – 54 years 
old) 
- 0. 1342 0.6700 - 0. 2864 0. 3870 
Elderly (55+ years old) 0. 3741 0.4540 0. 6623 0.2140 
PHDP*         
Undisclosed 0. 6968 0.0410 0. 5520 0.1390 
Adherence         
Fair (94 – 90%) - 0. 1453 0.6990 - 0. 3044 0.4420 
Poor (< 90%) 0.5800 0.5760 1. 7976 0.1170 
WHO Stage         
Severe disease (WHO 3 / 4) 1. 6632 0.0000 1. 2746 0.0010 
CD4 count         
201 – 350 cells/mm3 - 0. 4646 0. 1710 - 0. 2365 0.5320 
351 – 500 cells/mm3 - 1. 8730 0.0000 - 1. 9156 0.0010 
≥501 cells/mm3 - 2. 4524 0.0000 - 2. 7073 0.0000 
Time - 0.0389 0.0030 0.0401 0.0160 
• PHDP – Positive health, dignity, and prevention 
 
Adjusting for random effects and fitting a model illustrating determinants associated with 
viral load failure established that CD4 count levels, WHO stage, and time taken on ART were 
critical predictors of treatment failure. For each month a patient was on ART, there was a 
significant likelihood of having a detectable viral load of 4.0%, p=0.0160; those with 
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advanced WHO stage on the other hand were 1.66 more likely to have viral load failure, 
p=0.0010, compared to those with mild disease (WHO stage 1 or 2). Patients with CD4 
counts greater than 200 cells/mm3 had reduced likelihood of having detectable viral loads; 
those with counts between 351 and 500 cells / mm3 and greater had less than 1.92 times and 
2.71 times with p=0010 and p<0.0001 respectively. Relative to males, female patients on 
ART for at least six months had an insignificantly lower (aHR= 15.52%, p=0.5760) risk of 
failing therapy for the same (Figure 6).  
 
Figure 7: Instantaneous Hazards for ART Failure based on Viral Load Monitoring 
On the other hand, not having disclosed HIV status at the start of ART was associated with an 
all-time marginal increase in the risk of having detectable viral loads (aHR=17.7%), 
p=0.0930. All-time risk of patients with CD4 counts greater than 200 cells / mm3 reduced 
from 30.96% (201 – 350 cells / mm3) to 80.32% (351 – 500 cells / mm3) and 89.69% (>500 
cells / mm3) compared to those who record CD4 counts below 201 cells / mm3, p = 0.3250, 
p=0.0030, and p=0.0020 respectively. The incidence for detectable viral load was highest at 
six and 12 months of initiating therapy, rapidly declining in subsequent years of testing 
(Table 7).  
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Table 7: Hazard for ART Failure by Time Point 
Cohort  Person-time Failures Rate *PMFU (1000) 95% CI 
6 months 1704 20 11.74 7.57 18.19 
1 year 1584 18 11.36 7.16 18.04 
2 years 2952 5 1.69 0.7 4.07 
> 2 years 2892 4 1.38 0.52 3.69 
Overall  9132 47 5.15 3.87 6.85 
*PMFU – Patients Months of Follow Up 
After at least six months of taking ARVs, among the 93 male patients who accessed viral 
load, 20.4% had viral load counts greater than 1000 copies/ml compared to 14.8% of the 183 
female patients, but the difference was not significantly different with p = 0.6144. The 
Hazard Ratio (HR) for patients failing ART at Kakamega CGH by sex suggested that female 
adult patients on ART were 45.4% less likely to develop virologic failure compared to male 
adult patients-initiated ART in the same period, p=0.0470 (95% CI: 30.00% to 99.3%) 
(Figure7); however, there was not enough evidence suggesting  that hazards varied by sex, on 
adjusting for other variables (aHR 0.55; p=0.083), nor by age (aHR1.01; p=0.3770). Hazard 
rates were significantly dissimilar for baseline CD4 counts (aHR 1.0; p=0.026), and baseline 
WHO stage (aHR 1.64; p=0.007).  
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Figure 8: Kaplan-Meier Estimate for Viral Suppression on ART 
The incidence rate for virologic failure was 5.6 cases per 1000 patients-initiated ART per 
month of follow up (95% CI: 4.20 to 7.49); differing significantly between females (4.9 cases 
per 1000 female patients-initiated ART per month of follow up) and males (7.2 cases per 
1000 male patients-initiated ART per month of follow up), p= 0.0437).  
4.4. Program Retention 
The proportion of active patients on ART at the end of the study was 89.1 % (253), (p < 
0.0001). Among those who were not retained, 54.8% died while the rest were lost to follow 
up. The attrition rate was 3.4 cases per 1000 patients-initiated ART per month of follow up, 
95% CI: 2.4 to 4.9. The mortality rate on ART was 1.9 deaths per 1000 patients-initiated 
ART per month of follow up (95% CI: 1.2 to 3.0); while that of patients being lost to follow 
up was 1.5 cases per 1000 patients-initiated ART per month of follow up (95% CI: 0.9 to 
2.6). Among those that got lost, 8.3% were males compared to 12.2% who were females on 
ART follow up, but the difference was not statistically significant, p=0.5450. While there was 
no association between the patient being retained in the ART program and patient age group, 
p=0.9050, age group was found to confound the risk of attrition (aRR = 1.38; p=0.0375).  
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The mortality rates for males and females did not differ, p=0.6523, 1.6 male deaths per 1000 
patients on ART per month of follow up compared with 2.0 female deaths per 1000 patients 
on ART per month of follow up. There was no difference in the rates of lost to follow up 
between the sexes.; There were 1.0 cases of males being lost to follow-up per 1000 male 
patients initiated ART per month of follow up compared to 1.8 cases of female patients being 
lost to follow-up per 1000 female patients initiated ART per month of follow up in the clinic, 
p=0.3278 (figure 8).  
 
Figure 9: Kaplan Meier Estimate for Retaining Patients in ART Program at KCGH 
Relative to male patients on ART, female patients had an insignificantly higher hazard of not 
being retained into the ART program throughout the follow-up period (HR = 1.27; 
p=0.6530). The proportion of youths not being retained was 12.6% (12), whereas 9.9% (10) 
middle-aged patients either died or were lost to follow up, and, only 5.0% (1) of the elderly 
patients died (Figure 9).  
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Figure 10: Kaplan-Meier Estimates for Risk of Attrition by Death and Loss to Follow Up 
For every patient that had disclosed their HIV status at the start of the study that was not 
retained in the ART clinic, there was nearly a threefold increase in the risk of being lost 
among those who had not disclosed (aHR=2.9; p=0.0390). On the other hand, for each patient 
that was not retained in the clinic and was not suspected for treatment failure by WHO 
staging, had a significantly lower, three times, the risk of not being retained had they been 
suspected to have failed therapy by WHO staging (aHR=3.0; p=0.0410). Failing therapy 
identified by CD4 trend analysis was not associated with patient retention. There was a 
marginal significance in the risk of not being retained in the clinic if a patient was confirmed 
to have failed treatment by viral load count (aHR=2.43; p=0.0990).   
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CHAPTER FIVE 
DISCUSSION, CONCLUSION, AND RECOMMENDATIONS 
5.0. Introduction 
This chapter discusses the key findings of the study and compares these findings with other 
studies. The peculiarity of the study is highlighted and its limitations are presented. 
Recommendations that are aligned with the study findings are also given.  
5.1. Socio-demographics 
The study enrolled significantly fewer male adult patients than female adult patients initiating 
ART. It also had more youths amongst whom were more females than males. About half the 
proportion of youths were married. More than three-quarters of the patients in the study had 
disclosed their HIV status at the time they were being initiated ART. However, similar 
differences in gender were seen in a retrospective review done in Zimbabwe (129) where 
64.0% female participants were enrolled, and in an early cohort study among patients 
initiating ART in Ghana (136), 67.9% were female patients. (140) During the Kenya AIDS 
Indicators Survey of 2012, youths testing HIV positive accounted for 43.8% (284) while 
female participants who tested positive accounted for 70.2% (455). The Kenyan survey also 
found that HIV prevalence was high among females, 6.9% (95% CI: 6.0 to 7.7) compared to 
males 4.4% (95% CI: 3.6 to 5.2). These findings from the literature suggest that the 
sociodemographic profile for this study did not depart from previous studies conducted on 
HIV infection in Kenya and other near similar settings in Africa.  
5.2. ART Initiation and Context 
The World Health Organization published new guidelines on the use of antiretroviral drugs 
for treating and preventing HIV infection in June 2013, this was followed by the release of a 
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Rapid Advice on ART by the National AIDS and STI Control Program (NASCOP) in Kenya 
in May 2014, transitioning the country into new cut-offs and guidelines for initiating ART 
among HIV infected patients. Training of trainers was done by NASCOP in May 2014, and 
guidelines on the use of antiretroviral drugs for treating and preventing HIV infection in 
Kenya was released in June 2014. This study began in July 2014, at the wake of new 
treatment guidelines in which all adult and adolescent non-pregnant HIV infected patients 
with a CD4 count of 500 cells / mm3 were supposed to be initiated ART, or those with WHO 
staging 3 or 4 irrespective of CD4 counts; and, TDF based regimen is the preferred 
antiretroviral regime. 
A very high proportion of patients initiated ART based on CD4 counts most of whom were 
on a TDF based regimen. Merits and demerits of starting ART with high CD4 counts having 
been documented in multiple studies ((O’Connor et al., 2017) (141) (142)) point out that 
starting patients with high pretreatment CD4 counts has the benefits of reducing the risk of 
severe OIs accrued by improved immunological reconstitution, decreasing transmission of 
HIV infection, decreasing the risk of HIV related comorbidities such as cardiovascular 
disease (143). Few patients die due to HIV related deaths; however, due to better immunity 
(31) i.e. high CD4 counts, there are increased chances of suboptimal adherence to ART, 
especially among young patients which is a precursor for therapy failure, and transmission of 
resistant HIV strains (26).  
5.3. Primary Outcomes 
2.5.6 5.3.1. Clinical Outcomes 
Before ARVs were easily accessible, HIV infections and AIDS was commonly referred to as 
the “sliming disease” characterized by severe body weight and emaciation (144). Concerns 
have been raised over the rapid increases in weight and obesity among patients starting ART 
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(80), and, Yuh suggests that the rapid increase in weight in the initial months of therapy 
include a reduction in the metabolic demand from viral replication which suggests better 
clinical outcome (5). At KCGH, weight gain among study participants was not statistically 
significant to warrant investigating for unintentional causes of weight gain associated with 
dietary disorders, extraneous factors such as kidney disease, endocrine malfunctions or 
largely metabolic misnomers such as may arise with interactions with ARVs or other 
treatment substances used by patients  (80). An insignificant proportion of those who lost 
weight either died or required a change in therapy, this implies that the study participants 
were not at additional risk of poor immunological risks or of death in view of documented 
evidence (144). 
A significant reduction in the frequency of opportunistic infections was witnessed among 
patients upon initiating ART, and this benefit increased with time. Less than 20% of OIs 
should occur in patients on ART (59). Similarly, systematic reviews conducted to explore the 
prevalence and incidence of OIs with ART (13,145) have shown a marked reduction in WHO 
stage 3 or 4 OIs, but less so for PTB (146,147) possibly because of TB replaces and varied 
timing in initiating ART for patients with very low CD4 counts. In this study at least 30.8% 
of patients who were clinically staged WHO 3 or 4 had PTB; however, the overall rates of 
infection remained lower than 4.0% which was at least half the baseline rate. Nevertheless, 
recurrence of PTB is associated with patients failing therapy possibly because of poor 
adherence (122) since ART has been shown to significantly reduce the rates of TB infections 
(148).  
Response rates on ART for TB co-infected patients and those uninfected with TB have been 
shown to be similar (149). In the present study, there was no correlation between recurrent 
PTB infections and treatment failure, a finding reported by Khan et al. However, in the 
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systematic review by Khan, most PTB relapses were due to sub-optimal treatment with 
rifampicin suggesting at least 7 months of TB chemotherapy (148). There were no 
statistically significant differences between male and female patients with recurrent TB as 
was the case in a cross-sectional in South Africa (146), in which most of the patients were 
male, and had sputum negative results in their previous TB infection or had EPTB; or in an 
Indian cohort study whose participants had an history of higher than 19 mm Mantoux reading 
or used TB chemotherapy for less than 9 months (82). 
The dramatic decline in new OIs is associated with a reduction in the frequency of WHO 
stage 3 or 4. By suppressing the viral load, ARVs enable the multiplication of CD4 cells 
counts, and hence reducing the risk of OIs and HIV related malignancies (150) with the use 
of potent ART. 91.2% of the patients stayed on their initial regimen throughout the study 
period; as high as possible levels of retention on ART regimen is required (59). Yet, 
prolonged use of ART in the face of incomplete viral suppression is associated with extensive 
viral mutations favouring the development of drug-resistant viruses (151) which necessitate a 
change of regimen and switching to a higher level treatment options which become limited in 
the presence of drug-resistant strains (31). The importance of preserving treatment options 
longer, therefore, cannot be over-emphasized. The proportion of patients who switched to 
second-line ART was 2.1%, and this group as suggested by an Ethiopian cohort, and a 
modeling study is, again, due to poor adherence which leads to poor immune response 
(35,119). Poor adherence on ART is the commonest cause of unsuppressed viral load (76). 
While this study did not explore the factors associated with poor adherence, at least 30% of 
the patients on follow up had sub-optimal adherence i.e. less than 95% adherence to 
treatment. Mid-aged patients had better adherence compared to elderly patients who had the 
worst levels of optimal adherence to ART, and the study did not find a statistical difference in 
the adherence of male and female patients.   
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2.5.7 5.3.2. Immunological Response 
The study rhymes existing evidence that CD4 counts increase remarkably with the use of 
ART (19). Over 95% of the patients had optimal CD4 response with ART. But this contrasts 
with evidence that state that younger patients, those with advanced clinical stage, females, as 
well as those who with lower CD4 counts pre-treatment have better improvements in CD4 
counts (120,149) since elderly patients had a median increase of CD4 counts of 390 cells / 
mm3 compared to youths who had an increase of 320 cells / mm3 over the three years of 
follow up. However, more elderly patients (5%) were suspected to mount suboptimal 
improvements in CD4 counts which were nearly as twice the proportion for youths, a finding 
that partly agrees with that of a Swaziland survey (10). Similarly, despite female patients 
having better median CD4 count (315 cells/mm3) improvements over the three-year period 
compared to male patients (263 cells/mm3), this improvement was not statistically better than 
that of male patients. Male patients had better CD4 improvements by baseline CD4 category 
greater than 200 cells / mm3 over the three year period in contrast to a systematic review that 
pooled findings from Sub-Saharan Africa, Latin America and Asia (152).   
Discordant CD4 counts were suspected in two patients, whose counts remained below 100 
cells / mm3 at 6 months of therapy, and only increased by less than 50 cells / mm3 after a year 
of therapy. This paradoxical phenomenon in which CD4 count response to ART is poor is 
considered CD4 discordancy (104) and is related to suboptimal immune reconstitution. Kelly 
admits that discordant immune response (DIR) is largely looked at in two ways, by 
considering failure to achieve pre-specified absolute CD4 count values at predefined time 
points or, failure to achieve a pre-specified rise in CD4 count from baseline at predefined 
time points as was the case in this study. Of the two patients who had  DIR, the male patient 
died at 27 months of follow-up while the female patient was censored at the end of the study 
period. There was no data to support the actual cause of death in this patient that had DIR,. 
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There are possibilities that deaths in such patients, especially those that occur early in therapy 
are related to immune reconstitution inflammatory syndrome (IRIS), which is characterized 
by the exacerbation of an underlying OI that has not been sufficiently treated at the start of 
ART due to severe immunosuppression (31). 
Additional predictors based on multilevel modeling for factors associated with CD4 
outcomes confirmed that there was no statistical difference between CD4 response in male 
compared to female patients, detectable viral load was associated with increased CD4 failure, 
being an elderly patient, and pre-treatment advanced diseases and WHO stage 3 or 4 were 
associated with poor CD4 outcomes; similar findings were obtained in a retrospective cohort 
study done in Ethiopia on predictors of CD4 response. In the Ethiopian study, CD4 count 
increased by about 1.5 cells/mm3 per month of follow up, baseline age was negatively 
associated with CD4 count, sex was not found to be an independent predictor of CD4 
response, but time on ART was found to be an independent variate, and with lower CD4 
count pre-treatment, the higher the likelihood that the comparative increase in CD4 count will 
be relatively lower (92). On the other hand, following a prospective study at Johns Hopkins, 
Moore and Keruly suggest that most patients with baseline CD4 counts of at least 350 
cells/mm3 tend to achieve normal immune ranges while on ART (91). 
2.5.8 5.3.3. Virological Response 
HIV RNA viral load (VL) is an important measure of the efficiency of ART. Evidence 
suggests that VL is the single most reliable predictor of HIV disease progression (106). In 
Kenya, VL monitoring is not widely accessible except through secondary networking of 
patient samples. Over 98% of patients enrolled in this study accessed VL which was entirely 
through sample networking to reference laboratory in Western Kenya. At least 97% of 
patients whose samples were collected at six months, then at 12 months and thereafter yearly 
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had optimal VL response which is undetectable VL. The capacity to keep a patient’s VL 
undetectable for a long time has the promise of ensuring that the patient’s immune system is 
robust and it reduces the risk of morbidity and mortality among these patients to equal or 
better than those of the general population (152) and preserves potent ART treatment 
alternatives for them.  
The incidence rate for patients failing ART was highest in the first year of follow up and 
tremendously diminished in subsequent months (100). VL failure was 5.6 per 1000 patients 
after 36 ART months of follow up. 3% patients on first-line ART failed therapy; a finding 
that differs with a retrospective study done in Myanmar between 2005 and 2015 in which 
33% of the patients on ART failed therapy (100) in Myanmar which had an incidence rate of 
3.2 per 100 person-years of follow-up. In the Myanmar study, routine VL monitoring was not 
readily available and 58% of the patients were male. A prospective cohort study in China 
established a virologic failure of 11% which was more common among patients initiated 
NNRTIs, male patients and had resistant HIV strains at 5%, commonly K103N and M184V 
(106), and yet in a Kenyan study, 23% of patients were confirmed to have failed therapy 
(102). In the present study, female patients were less likely to have detectable viral loads aHR 
17.7 though this was not statistically significant as adherence on ART did not vary by sex 
contrasting with the Chinese study Abdissa in which fewer women missed their ART.  
Middle-aged female patients in this study had better VL outcomes compared to their male 
counterparts. Nonetheless, female patients who experienced adverse drug effects were more 
likely to end up with VL failure compared to male patients (106); suggesting that women had 
better adherence behavior until life-threatening events related to the medication happened to 
them. Disclosure status at the start of ART in this study was found to be a predictor of VL 
failure. Youths who had not disclosed their status were at a higher risk of VL failure 
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compared to the others (100); emphasizing the need to address disclosure at the start of ART 
especially among young people, and by extension suggesting the importance of treatment 
buddies for ART. Suboptimal response to therapy is associated with poor adherence (153) 
which is also related to a lack of disclosure of HIV status. 
Among patients confirmed to have failed therapy, 80% (38) who had detectable viral load 
counts, were patients with pre-treatment CD4 counts less than 351 cells / mm3 which matches 
findings from the literature that higher pretreatment CD4 counts are protective of VL failure 
(26). But, for every month a patient was on ART, the probability of such a patient failing VL 
were as high as 4% especially so among elderly patients, finding which differs with a study 
conducted in Cameroon that disputed any relationship between failing viral load among 
adolescent patients and  time (22) and partly with a study conducted in Ethiopia which found 
that youths with low CD4 counts, poor adherence to treatment and experienced on ART, were 
positively and significantly associated with VL failure (154).  
Considering that no viral load was done at baseline, patients were also monitored for viral 
blips. A transient rise in viral load levels above undetectable levels to counts below 
thresholds considered virologic failure (99). Importantly so because literature confirms that 
viral blips are as frequent as 22.7% among patients with suppressed viral loads on ART and 
such incidences occurring in about three consecutive occasions are highly associated with 
virologic failure (125). (99) highlights that viral blips are common among patients on 
NNRTIs compared to the other drug regimen, however, all patients in the study were initiated 
therapy on NNRTI based regimen. However, a breakdown of the six patients who had 
episodes of viral blips indicates that 66.67% of these patients were on EFV containing 
regimes, in which three-quarters of those patients on EFV containing regimes were on TDF. 
Fortunately, none of the documented cases failed virologically.  
http://etd.uwc.ac.za/
 52 
 
2.5.9 5.3.4. Program Retention 
A high retention of 89% was found in this study similar to that done in Myanmar of 84% 
(130); but this level of retention is considerably higher than that in literature as documented 
by a systematic review conducted on Sub-Saharan Africa of 78% (128) and much lower at 
65% at 36 months of follow up (155). Yet, program retention is such an important marker for 
ART programs because it tells how well the ARVs have averted mortalities and morbidities 
(Fox & Rosen, 2015). The incidence of deaths (55%) was higher than patients getting lost to 
follow up (45%), unlike evidence in literature in which deaths accounted for 43% and the rest 
of the majority were lost to follow up (Fox & Rosen, 2015).  
74% of female patients were less likely to be retained in the program and still accounted for a 
higher proportion of those who died or got lost compared to male patients on ART, and at the 
same time, those who had CD4 counts less than 200 cells / mm3 were more likely to die 
(73%) compared with the rest, whereas those who had CD4 counts between 201 and 350 
were more likely (64%) to be lost to follow up. This is similar with (Fox & Rosen, 2015) 
findings that those who had AIDS-defining CD4 counts were less likely to be retained 
compared with the other patients, but also pointed out that female patients were better 
retained than male patients. 13% of youths were equally less likely to be retained although 
this was not seen to be associated with adherence in the study nor disclosure status. (156) 
highlight that poor retention in HIV programs in resource-limited settings like KCGH is 
related to multiple factors relating to health systems, the community from which the patient 
comes and, individual patient factors.  
5.4. Secondary Outcome 
Suitability of Clinical Based Monitoring of Treatment Failure  
Using the clinical criteria to screen for patients suspected of dealing with failure, the study 
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established that the WHO criteria for the detection of treatment failure had a sensitivity of 
80% but a slightly higher specificity of 87%. The chance that someone would be identified as 
a treatment failure given they have failed therapy was 57%. However, studies elsewhere 
reported much lower performance for these screening criteria which was lower than 14% 
sensitivity, as high as 98% specificity and, as low as 20% positive predictive value (37), 
elsewhere, these criteria were found to inaccurately identify virological failure among 
children on ART (108).  
5.5. Study Limitations and Bias 
This was a retrospective study that relied on information generated for clinical care and 
follow up of patients. The data used therefore was not complete. Medical records in the clinic 
were also undergoing reconstruction and validation, and only data for patients started on ART 
between July 2014 and March 2015 could be accessed and used in the study. Hence, the study 
could not control for information and measurement biases arising due to documentation 
errors.  
Measurement bias could not be overcome considering this study was retrospective and 
relied on secondary data, but the stratification and regression analysis was done to address 
this. However, a sensitivity analysis was not done since it had not been considered at the 
design phase. 
Selection bias was a possible source of errors; however, all eligible subjects in the study 
population and for the study period whose records were available were included in the 
study. There still exists potential bias considering generalizability. and the way the study 
population and its target population are compared. This study could not ascertain the 
accuracy of all the clinical and laboratory information such as WHO staging, CD4 count 
and viral load results that were collected for every single client in the study, and so, bias 
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and confounding could only be reduced during data analysis. For example, CD4 results 
were matched and compared by gender and months on follow up, and this applied in each 
treatment outcome. Nonetheless, unmeasured confounding could potentially affect the 
results of this study. 
Finally, the study period and scope were limited to explore additional predictors and 
various methods of generating rich information were used to explain some of the study 
findings. An exploratory qualitative study would help understand what happens with 
female patients who experience adverse drug events that lead them to fail therapy; could 
they be feigning compliance? 
 
5.6. Conclusion 
This study established that a high proportion of patients had a remarkable improvement in 
their clinical condition, CD4 counts and viral load upon initiating on their first line regimen. 
However, a critical proportion of patients failed therapy and require to be transitioned to 
second line ART regimen. The clinical criteria for identifying treatment failure had better 
performance in this study compared with that in literature, but viral load monitoring remains 
gold standard. Whereas retention in ART program was high, more needs to be done to 
achieve at least 90% of the UNAIDS goal for patient retention particularly to address 
underlying system level, community, and individual patient treatment support and adherence.  
5.7. Recommendations 
1. With a high proportion of patients with recurrent WHO stage 3 or 4 diseases being 
confirmed to fail therapy or being lost in the ART program, there is a need to 
continuously screen and manage those at risk and with the disease to prevent negative 
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outcomes. Such management may include psychosocial care that may address non-overt 
challenges with therapy adherence and treatment support. 
2. CD4 monitoring at least every six months should be encouraged to ensure closer 
monitoring of immunological progression as well as the screening of patients who may be 
at risk of death due to conditions or OIs arising from non-responsive or failing immunity. 
Such patients are also at high risk of failing ART. 
3. Viral load monitoring should be enforced as the gold standard to monitoring treatment 
response and those with viral blips as well as those suspected to be failing virologically 
should be screened for poor adherence, immunological failure, and presence of resistant 
HIV strains. 
4. For enhanced retention in ART programs, there is a need to explore and address health 
systems, clinics, community, and individual level barriers and facilitators to retention. 
5. The use of clinical criteria for identifying ART failure should be promoted in the 
routine clinical care of patients on ART especially where viral load monitoring is not 
timeously available. Further investigation should be conducted into the efficiency of 
these criteria in the current context of test and treat and in varied contexts and. 
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Appendix I: Maps for Kenya and Kakamega County 
 
Source: http://www.kenyampya.com/index.php?county=Kakamega  
http://etd.uwc.ac.za/
 82 
 
Appendix II: Chart Abstraction Tool  
ART Chart Abstraction Tool 
General Details Section 
Unique ID ……………………… Date Born …/…/… Age ……… 
Patient’s Location Available: Yes … No … Patient Has Treatment Supporter: (Check) Yes … 
No … 
Date HIV diagnosis …/…/… Date Enrolled …/…/…  Date Started ART …/…/… 
Follow up Ended: Yes … No … Date Follow up Ended …/…/… 
Reason for Termination: Transferred Out … Died … LTFU* … Discontinued ART … 
Unknown … 
Treatment History Section 
Laboratory Test:                 Date:          ARV Regimen:                              Date:            Duration on Rx: 
CD4 at enrolment ……    …./…./….   Current Regimen ……………      …/…/…       
………Months 
CD4 at ART start ……    …./…/….    Past Regimen       ……………      …/…/…       
………Months  
Baseline Viral load ……    …./…/….   Past Regimen       ……………      …/…/…       
………Months 
Follow up Viral load …..    …/…/…    Past Regimen       ……………      …/…/…       
………Months 
Follow up Viral load …..    …/…/…     CD4 at suspected Failure ……      …/…/…  
Opportunistic Infections History 
Name MM / YY MM / 
YY  
Name MM / 
YY 
MM / 
YY 
PTB:  / / Cryptococcal Meningitis / / 
Smear + Smear 
- / 
/ 
Encephalopathy / Dementia 
/ / 
Extra Pulmonary TB 
/ 
/ 
Neuro (Toxo, PML, 
lymphoma) 
/ 
/ 
PCP / / Chronic diarrhoea / Wasting / / 
Pneumonia / / Salmonellosis / / 
Mycobacteria other / / Septicemia / / 
Oral Thrush / / KS – Cutaneous / / 
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Oesophageal 
Candidiasis / 
/ 
KS – Visceral 
/ 
/ 
CMV retinitis / / Genital ulcerative disease / / 
Herpes zoster / / Urethritis / cervicitis / / 
Herpes simplex / / PID / / 
Lymphoma / / Other / / 
Other / / Other / / 
Section on Routine Visit Tallies 
Date Weight Height Missed 
Drug 
Neck 
Stiff 
Photo- 
phobia 
Mental  
State 
Opportunistic Infection  WHO 
stage 
CD4 
Count 
Viral 
Load 
ART change 
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Appendix III: Permission to Review and Access Patient Records at Kakamega 
County General Hospital 
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Appendix IV: BMREC Letter 
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